The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
about
To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?Sex and Gender Differences in Central Nervous System-Related DisordersOestrogen has neuroprotective effects and may reduce the risk of Alzheimer's disease.Defining meaningful change in Alzheimer's disease trials: the donepezil experience.Sample size determination in group-sequential clinical trials with two co-primary endpoints.Sex differences in cognitive impairment and Alzheimer's disease.Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON).Hormone-dependent aging problems in women.CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's diseaseThe tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampusCombination pharmacotherapy in Alzheimer's diseaseHormone therapy and Alzheimer's disease: benefit or harm?An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.Target symptoms and outcome measures: cognition.Disease staging and milestones.Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause.Issues in evaluation of cognition in the elderly in developing countries.Longitudinal clinical score prediction in Alzheimer's disease with soft-split sparse regression based random forest.Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patientsOutcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.Identification of progressive mild cognitive impairment patients using incomplete longitudinal MRI scans.Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice.Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.Converting cognitive screening instrument test scores to MMSE scores: regression equations.Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.Is there correlation between cognition and functionality in severe dementia? the value of a performance-based ecological assessment for Alzheimer's disease.Resting-State Functional Connectivity Predicts Cognitive Impairment Related to Alzheimer's Disease.
P2860
Q24800672-2EF084C6-A028-4680-BE23-7146E8632B84Q26744569-F8592A81-85AE-49F4-A69F-E0913CE9FDB5Q30712450-3EF377AF-875E-4BC6-B86B-013DA715A585Q33711100-3AD89D9C-BAAC-478F-9792-58FAC4FB30FAQ33848180-F5483206-06B2-457A-8840-BDEDD5BCDCDBQ33864547-8C0D388D-D07D-4DFC-BD3F-493AF3F8C1BCQ34381707-4C44990F-D1FB-4078-B287-C8FF9E10B4F8Q34593579-13641F52-ADEF-485C-9EC7-B7DB8F9520A7Q35082774-8C5EE43A-1D68-477E-B473-C51AC57DA45EQ35118037-42BF6495-F511-465F-B5B9-4CD001B85638Q35236346-EFBDF6B2-C747-41AD-AF6B-DF7D4358C30AQ35680612-B22237DC-D754-4C8B-BB28-F57E841D5438Q36372366-06F0DC72-E8C3-4E99-BC66-C1578E97A6CFQ36436653-D31110CA-6C3B-4373-BD83-EA60B230674CQ36806620-8284D30A-12AE-4D03-A587-DF7A21E0C834Q36806639-356B2CC2-26A8-43F9-AF3C-03305A487E07Q36887336-0C43D15E-43BE-4076-959F-AE74F61F8032Q37315515-D45A4807-CB41-425A-B711-5373B24775B8Q37409043-C43BF984-036F-4F88-B835-248792ADC9E5Q37495065-E517A492-963D-4268-87FB-F111BFAF7E20Q37563867-DB88D8E5-D3C8-40C6-AF76-F9F148769F43Q37730520-156EF79E-0E17-483B-AAB2-954F14E936EAQ38398560-B583745F-D625-4925-BF8B-6234548B97EEQ38893744-3095DEEC-BD61-4BCE-AC66-448DC2155BA1Q39740912-8B894D5F-40D3-430F-9CB6-E8E5A5928CACQ40279123-862FECDD-AB93-414F-BD9E-8A7802A8BCB4Q42760171-4699B979-857D-481E-96F3-8C2FF7A3BD79Q43028519-EE21FBBD-43EA-487B-9E33-F58FF95671A1Q44670935-153A63ED-6446-48A3-AB30-FA464A2E9BB0Q46506219-B66398C5-4120-4E19-BE5B-5989864B18A8Q47223773-B0940A42-C8C5-458C-9FAA-662BE0B661D5Q47981470-98A451F4-EC34-45C6-9B4B-8718BEB49BCCQ48682941-8FA598C2-6B4A-40E2-91E8-11ADD1476128Q50611564-2D24BF53-5E29-4B55-B2BA-F7940406C210Q53397639-A097488D-400A-4F27-9B33-8F162A8DC2A5
P2860
The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@ast
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@de
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@en
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@fr
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@nl
type
label
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@ast
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@de
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@en
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@fr
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@nl
prefLabel
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@ast
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@de
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@en
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@fr
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@nl
P2093
P356
P1433
P1476
The Alzheimer's Disease Assess ...... er Alzheimer's disease trials.
@en
P2093
Doraiswamy PM
Gulanski B
Krishnan KR
Reuning-Scherer J
P304
P356
10.1212/WNL.48.6.1511
P407
P577
1997-06-01T00:00:00Z